Pharmabiz

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...
LancsLive on MSN

UK asthma sufferers issued 'little-known problem' NHS alert by GP

Data from Asthma and Lung UK reveals that 7.2 million people in the UK have asthma, equating to roughly eight in every 100 ...

NHS GP 'little known' asthma alert issued to 7.2 million UK sufferers

Data from Asthma and Lung UK reveals that 7.2 million people in the UK have asthma, equating to roughly eight in every 100 individuals. Those with asthma may experience symptoms such as wheezing, ...

How 'His & Hers' Pulled Off That Jaw-Dropping Plot Twist

A significant plot twist is all but guaranteed to come next. The Netflix series His & Hers opts for this tried-and-tested ...

‘I piled on weight within weeks when I stopped fat jabs, my munchies were so bad my partner had to padlock the fridge’

FAT jabs have worked for millions but a new study warns users may need to stay with the pricey drugs for life – or risk ...
Pharmabiz

AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity

AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity ...
EuropaWire

GSK Receives Japanese Approval for Exdensur as Twice-Yearly Treatment for Severe Asthma and CRSwNP

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...
Medscape

Twice-Yearly Asthma Biologic Gains UK Approval

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved depemokimab (Exdensur, GSK plc) as add-on therapy for severe asthma and for chronic rhinosinusitis with nasal polyps (CRSwNP ...
Reuters

UK approves GSK's twice-yearly asthma drug

Dec 15 (Reuters) - UK's health regulator on Monday approved GSK's (GSK.L), opens new tab twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a ...
MedPage Today

First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...
Open Access Government

Digital platforms are recommended to support asthma management

People living with asthma could gain better access to digital tools to help them better manage their condition ...
Computer Weekly

UK government confirms Foreign Office cyber attack

The UK government has admitted that IT systems at the Foreign, Commonwealth and Development Office (FCDO) were hacked in October, but insists the attack had a “low risk” of personal data being ...